Heparin-induced thrombocytopenia with acute aortic and renal thrombosis in a patient treated with low-molecular-weight heparin
Case report published in Eur J Vasc Endovasc Surg (2005)
Abstract
Heparin-induced thrombocytopenia is a rare but serious complication of heparin therapy. Most of cases are related to unfractionated heparin, but a few are due to low molecular weight heparin sometimes associated with unfractionated heparin. A patient with pulmonary contusions after chest injury developed a catheter related subclavian vein thrombosis on day 16. He was treated by increasing doses of low molecular weight heparin. Aortic and renal thromboses occurred on day 21. Surgical thrombectomy, performed after starting alternative anticoagulation treatment led to complete arterial recovery. In case of suspicion of heparin-induced thrombocytopenia, with unfractionated or low-molecular-weight heparin, heparin treatment must be discontinued before the results of biological tests become available. Arterial and/or venous thrombosis is a serious complication of heparin-induced thrombocytopenia. The treatment has two aims: first, to restore arterial patency by clot removal by thrombectomy, bypass or thrombolysis, and second, to avoid new thrombosis formation by substitutive anticoagulation treatment: danaparoid may have cross-reaction with heparin, or lepirudin has anaphylactic risks and needs biological follow-up. Heparin-induced thrombocytopenia and thrombosis can be complicated by death or disabilities such as amputations, stroke, renal or bowel infarction. Once HIT has been diagnosed heparin should never be given again, but if cardiopulmonary bypass is required, it might be reintroduced during operation only if serum antibodies have disappeared.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Polytrauma patient developed HIT and acute aortic/renal thrombosis after LMWH; surgical thrombectomy under alternative anticoagulation including lepirudin restored arterial patency.
Why This Matters for Hirudotherapy
This case report describes heparin-induced thrombocytopenia (HIT) complicated by acute aortic and renal thrombosis in a trauma patient receiving low-molecular-weight heparin, managed with surgical thrombectomy and alternative anticoagulation. The abstract specifically identifies lepirudin — recombinant hirudin derived from the medicinal leech Hirudo medicinalis — as a substitute anticoagulant option in HIT, while noting its anaphylactic risk and requirement for biological monitoring. For ASH and hirudotherapy, this illustrates a clinically significant context in which a leech-secretome-derived anticoagulant serves as a recognized therapeutic alternative when heparin is contraindicated due to life-threatening thrombotic complications. The honest caveat is that this is a single case report documenting management options, not an efficacy study of lepirudin or other hirudin-based therapies; the abstract mentions lepirudin only as one option alongside its risks.
Citation
Heparin-induced thrombocytopenia with acute aortic and renal thrombosis in a patient treated with low-molecular-weight heparin.
Chevalier J et al. · European journal of vascular and endovascular surgery, 2005
Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026